Skip to content

Study · Animal study (in vivo) · rat · 2003

12 results

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.

Sturis J, Gotfredsen CF, Rømer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, Carr RD, Knudsen LB

British journal of pharmacology29 Jul 2003Cited by 157 (Europe PMC)

PMID12967942 (opens in a new tab)PMCIDPMC1573996 (opens in a new tab)DOI10.1038/sj.bjp.0705397 (opens in a new tab)PepBankPUB-12967942
Source linkPubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Zucker diabetic fatty rats, liraglutide markedly attenuated diabetes development over 6 weeks.

    In plain wordsIn rats prone to diabetes, liraglutide strongly slowed the development of diabetes.

    Peptide
    Liraglutide
    Outcome
    DecreaseDiabetes development in ZDF rats
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    150 microg/kg twice daily · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    (2) When liraglutide was dosed s.c. at 150 microg kg-1 b.i.d. for 6 weeks in ZDF rats 6-8 weeks of age at study start, diabetes development was markedly attenuated.
    1 context sentence
    Summary · context
    To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Zucker diabetic fatty rats, blood glucose was approximately 12 mm lower with liraglutide than with vehicle.

    In plain wordsIn rats prone to diabetes, liraglutide lowered blood sugar compared with vehicle.

    Peptide
    Liraglutide
    Outcome
    DecreaseBlood glucose in ZDF rats
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    150 microg/kg twice daily · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    Blood glucose was approximately 12 mm lower compared to vehicle (P<0.0002)
    1 context sentence
    Summary · context
    To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In Zucker diabetic fatty rats, plasma insulin was 2-3-fold higher with liraglutide than with vehicle during a normal 24-h feeding period.

    In plain wordsIn rats prone to diabetes, liraglutide raised blood insulin 2 to 3 times compared with vehicle.

    Peptide
    Liraglutide
    Outcome
    IncreasePlasma insulin in ZDF rats
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    150 microg/kg twice daily · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    and plasma insulin was 2-3-fold higher during a normal 24-h feeding period (P<0.001).
    1 context sentence
    Summary · context
    To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In Zucker diabetic fatty rats, liraglutide reduced food intake by an average of 16%, persisting throughout the study.

    In plain wordsIn rats prone to diabetes, liraglutide reduced food intake by about 16% throughout the study.

    Peptide
    Liraglutide
    Outcome
    DecreaseFood intake in ZDF rats
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    150 microg/kg twice daily · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    which persisted throughout the study and averaged 16% (P<0.02).
    1 context sentence
    Summary · context
    To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In Zucker diabetic fatty rats, pair feeding indicated that approximately 53% of the antihyperglycemic effect of liraglutide was mediated by reduced food intake.

    In plain wordsIn rats prone to diabetes, about half of liraglutide's blood sugar lowering was due to eating less.

    Peptide
    Liraglutide
    Outcome
    Not applicableShare of antihyperglycemic effect due to reduced food intake
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Pair-fed vehicle rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    150 microg/kg twice daily · subcutaneous · 6 weeksAs given in this study (rat).

    Measurements

    Share of effect mediated by food intake
    ≈ 53%
    ZDF rats

    Source sentences

    Summary
    Judged by pair feeding, approximately 53% of the antihyperglycemic effect observed on 24-h glucose profiles was mediated by a reduction in food intake
    1 context sentence
    Summary · context
    To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In prediabetic Zucker diabetic fatty rats, beta-cell mass was significantly lower after 2 weeks of liraglutide than in vehicle-treated rats that had begun to develop diabetes.

    In plain wordsIn prediabetic rats, beta-cell mass was lower after 2 weeks of liraglutide than in vehicle rats that were developing diabetes.

    Peptide
    Liraglutide
    Outcome
    DecreaseBeta-cell mass after 2 weeks in prediabetic ZDF rats
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    150 microg/kg twice daily · subcutaneous · 2 weeksAs given in this study (rat).

    Source sentences

    Summary
    (3) Histological analyses revealed that beta-cell mass and proliferation were significantly lower in prediabetic animals still normoglycemic after 2 weeks treatment compared to vehicle-treated animals that had begun to develop diabetes.
    1 context sentence
    Summary · context
    To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In prediabetic Zucker diabetic fatty rats, beta-cell proliferation was significantly lower after 2 weeks of liraglutide than in vehicle-treated rats that had begun to develop diabetes.

    In plain wordsIn prediabetic rats, beta-cell growth was lower after 2 weeks of liraglutide than in vehicle rats that were developing diabetes.

    Peptide
    Liraglutide
    Outcome
    DecreaseBeta-cell proliferation after 2 weeks in prediabetic ZDF rats
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    150 microg/kg twice daily · subcutaneous · 2 weeksAs given in this study (rat).

    Source sentences

    Summary
    (3) Histological analyses revealed that beta-cell mass and proliferation were significantly lower in prediabetic animals still normoglycemic after 2 weeks treatment compared to vehicle-treated animals that had begun to develop diabetes.
    1 context sentence
    Summary · context
    To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In Zucker diabetic fatty rats, after 6 weeks of liraglutide beta-cell mass was significantly increased compared with overtly diabetic vehicle-treated rats.

    In plain wordsIn rats prone to diabetes, 6 weeks of liraglutide gave more beta-cell mass than in diabetic vehicle rats.

    Peptide
    Liraglutide
    Outcome
    IncreaseBeta-cell mass after 6 weeks in ZDF rats
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    150 microg/kg twice daily · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    When the treatment period was 6 weeks, the liraglutide-treated animals were no longer completely normoglycemic and the beta-cell mass was significantly increased compared to overtly diabetic vehicle-treated animals
    1 context sentence
    Summary · context
    To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In Zucker diabetic fatty rats, beta-cell proliferation was unaffected after 6 weeks of liraglutide.

    In plain wordsIn rats prone to diabetes, 6 weeks of liraglutide did not change beta-cell growth.

    Peptide
    Liraglutide
    Outcome
    No significant changeBeta-cell proliferation after 6 weeks in ZDF rats
    Study

    ratn: not reported in source

    Zucker diabetic fatty rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    150 microg/kg twice daily · subcutaneous · 6 weeksAs given in this study (rat).

    Source sentences

    Summary
    while beta-cell proliferation was unaffected.
    1 context sentence
    Summary · context
    To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In 60% pancreatectomized rats, 8 days of liraglutide significantly lowered the glucose excursion after oral glucose compared with vehicle.

    In plain wordsIn rats with part of the pancreas removed, liraglutide lowered the blood sugar rise after a sugar drink compared with vehicle.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlucose excursion to oral glucose in pancreatectomized rats
    Study

    ratn: not reported in source

    60% pancreatectomized rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 8 daysAs given in this study (rat).

    Source sentences

    Summary
    (4) In the experiments with 60% pancreatectomized rats, 8 days treatment with liraglutide resulted in a significantly lower glucose excursion in response to oral glucose compared to vehicle treatment.
    1 context sentence
    Summary · context
    To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In 60% pancreatectomized rats, part of the antihyperglycemic effect of liraglutide was due to reduced food intake.

    In plain wordsIn rats with part of the pancreas removed, part of liraglutide's blood sugar effect came from eating less.

    Peptide
    Liraglutide
    Outcome
    DecreaseFood intake in pancreatectomized rats
    Study

    ratn: not reported in source

    60% pancreatectomized rats
    Comparator
    Vehicle
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 8 daysAs given in this study (rat).

    Source sentences

    Summary
    Again, part of the antihyperglycemic effect was due to reduced food intake.
    1 context sentence
    Summary · context
    To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In virtually normoglycemic 60% pancreatectomized rats, liraglutide had no effect on beta-cell mass.

    In plain wordsIn rats with part of the pancreas removed and near-normal blood sugar, liraglutide did not change beta-cell mass.

    Peptide
    Liraglutide
    Outcome
    No significant changeBeta-cell mass in pancreatectomized rats
    Study

    ratn: not reported in source

    60% pancreatectomized rats
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 8 daysAs given in this study (rat).

    Source sentences

    Summary
    No effect of liraglutide on beta-cell mass was observed in these virtually normoglycemic animals.
    1 context sentence
    Summary · context
    To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.